Tyrosine kinase receptor
From Proteopedia
(Difference between revisions)
| Line 24: | Line 24: | ||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| + | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | *Tyrosine kinase receptor or high affinity nerve growth factor receptor; Domains – extracellular 36-382; LBD 285-380; transmembrane 410-447; kinase 498-796 | + | *Tyrosine kinase receptor-A or high affinity nerve growth factor receptor; Domains – extracellular 36-382; LBD 285-380; transmembrane 410-447; kinase 498-796 |
| - | [[1he7]] – hTRK-A LBD domain – human <BR /> | + | **[[1he7]] – hTRK-A LBD domain – human <BR /> |
| - | [[4crp]] – hTRK-A LBD domain (mutant) – NMR<br /> | + | **[[4crp]] – hTRK-A LBD domain (mutant) – NMR<br /> |
| - | [[2ifg]] – hTRK-A extracellular domain + b-nerve growth factor <BR /> | + | **[[2ifg]] – hTRK-A extracellular domain + b-nerve growth factor <BR /> |
| - | [[4gt5]], [[4f0i]]] – hTRK-A kinase domain<BR /> | + | **[[4gt5]], [[4f0i]]] – hTRK-A kinase domain<BR /> |
| - | [[5kvt]], [[6pl1]], [[6npt]], [[6nsp]], [[6nss]], [[5wr7]], [[6d1y]], [[6d1z]], [[6pmc]], [[6iqn]], [[6pl2]], [[6pl3]], [[6pma]], [[6pmb]], [[6pme]], [[5kmj]], [[5kmk]], [[5kmm]], [[5kmn]], [[5kmo]], [[4aoj]], [[4pmm]], [[4pmp]], [[4pms]], [[4pmt]], [[4yps]], [[5h3q]], [[5i8a]], [[5kmi]], [[5kml]], [[6d20]], [[6dkb]], [[6dkg]], [[6dki]], [[6j5l]], [[5jfs]], [[5jfv]], [[5jfw]], [[5jfx]], [[4yne]], [[6dkw]] – hTRK-A kinase domain + inhibitor<BR /> | + | **[[5kvt]], [[6pl1]], [[6npt]], [[6nsp]], [[6nss]], [[5wr7]], [[6d1y]], [[6d1z]], [[6pmc]], [[6iqn]], [[6pl2]], [[6pl3]], [[6pma]], [[6pmb]], [[6pme]], [[5kmj]], [[5kmk]], [[5kmm]], [[5kmn]], [[5kmo]], [[4aoj]], [[4pmm]], [[4pmp]], [[4pms]], [[4pmt]], [[4yps]], [[5h3q]], [[5i8a]], [[5kmi]], [[5kml]], [[6d20]], [[6dkb]], [[6dkg]], [[6dki]], [[6j5l]], [[5jfs]], [[5jfv]], [[5jfw]], [[5jfx]], [[4yne]], [[6dkw]] – hTRK-A kinase domain + inhibitor<BR /> |
| - | [[2n90]] – hTRK-A transmembrane domain - NMR <BR /> | + | **[[2n90]] – hTRK-A transmembrane domain - NMR <BR /> |
| + | *TRK-B or BDNF/NT-3 growth factor receptor | ||
| + | |||
| + | **[[1wwb]] – hTRK-B LBD domain <BR /> | ||
| + | **[[1hcf]] – hTRK-B LBD domain + neutrotrophin-4<BR /> | ||
| + | **[[5mo9]] – hTRK-B LBD domain + antibody<BR /> | ||
| + | **[[4asz]] – hTRK-B kinase domain<BR /> | ||
| + | **[[4at3]], [[4at4]], [[4at5]] – hTRK-B kinase domain + inhibitor<BR /> | ||
| + | |||
| + | *TRK-C or NT-3 growth factor receptor | ||
| + | |||
| + | **[[1wwc]4pbv] – hTRK-C LBD domain (mutant)<BR /> | ||
| + | **[[4pbv]], [[4pbw]] – hTRK-C extracellular domain (mutant) + tyrosine phosphatase s<BR /> | ||
| + | **[[3v5q]], [[4ymj]], [[6kzc]], [[6kzd]] – hTRK-C kinase domain + inhibitor<BR /> | ||
| + | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 09:34, 31 March 2020
| |||||||||||
3D Structures tyrosine kinase receptor
Updated on 31-March-2020 {{#tree:id=OrganizedByTopic|openlevels=0|
- Tyrosine kinase receptor-A or high affinity nerve growth factor receptor; Domains – extracellular 36-382; LBD 285-380; transmembrane 410-447; kinase 498-796
- 1he7 – hTRK-A LBD domain – human
- 4crp – hTRK-A LBD domain (mutant) – NMR
- 2ifg – hTRK-A extracellular domain + b-nerve growth factor
- 4gt5, 4f0i] – hTRK-A kinase domain
- 5kvt, 6pl1, 6npt, 6nsp, 6nss, 5wr7, 6d1y, 6d1z, 6pmc, 6iqn, 6pl2, 6pl3, 6pma, 6pmb, 6pme, 5kmj, 5kmk, 5kmm, 5kmn, 5kmo, 4aoj, 4pmm, 4pmp, 4pms, 4pmt, 4yps, 5h3q, 5i8a, 5kmi, 5kml, 6d20, 6dkb, 6dkg, 6dki, 6j5l, 5jfs, 5jfv, 5jfw, 5jfx, 4yne, 6dkw – hTRK-A kinase domain + inhibitor
- 2n90 – hTRK-A transmembrane domain - NMR
- 1he7 – hTRK-A LBD domain – human
- TRK-B or BDNF/NT-3 growth factor receptor
- TRK-C or NT-3 growth factor receptor
}}
References
- ↑ Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018 Feb 19;17(1):58. doi: 10.1186/s12943-018-0782-4. PMID:29455648 doi:http://dx.doi.org/10.1186/s12943-018-0782-4
- ↑ Deinhardt K, Chao MV. Trk receptors. Handb Exp Pharmacol. 2014;220:103-19. doi: 10.1007/978-3-642-45106-5_5. PMID:24668471 doi:http://dx.doi.org/10.1007/978-3-642-45106-5_5
- ↑ Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathol. 2014 Aug;27(8):1050-62. doi: 10.1038/modpathol.2013.233. Epub 2014, Jan 3. PMID:24390213 doi:http://dx.doi.org/10.1038/modpathol.2013.233
- ↑ Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med Chem Lett. 2015 Mar 16;6(5):562-7. doi: 10.1021/acsmedchemlett.5b00050., eCollection 2015 May 14. PMID:26005534 doi:http://dx.doi.org/10.1021/acsmedchemlett.5b00050
- ↑ Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 2007 Jan 4;53(1):25-38. PMID:17196528 doi:10.1016/j.neuron.2006.09.034
